FDA Sets Review Timeline for MEDIBEACON Patent Extension
Published Date: 1/5/2026
Notice
Summary
The FDA has officially set the review period for MEDIBEACON, a medical device, which helps the company apply for extra patent time. This means the makers can potentially extend their patent protection, giving them more time to benefit financially. Anyone interested has until March 6, 2026, to share their thoughts with the FDA.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 0 costs, 2 mixed.
FDA Sets Patent Review Period
The FDA determined MEDIBEACON's regulatory review period is 4,175 days in total — 3,598 days in the testing phase and 577 days in the approval phase. That determination establishes the maximum potential length of a patent extension; the applicant seeks 5 years of patent term extension (the PMA was approved January 17, 2025).
MEDIBEACON Approval & Use Limits
MEDIBEACON was approved (PMA P230019) on January 17, 2025 to assess glomerular filtration rate (GFR) in adult patients by noninvasively monitoring fluorescent light from an injected tracer. The device is validated in patients with stable renal function but is not approved for use in patients with GFR 120 ml/min/1.73m2, patients on dialysis, or anuric patients, and it is not intended to diagnose acute kidney injury; the TGFR Sensor and Lumitrace injection are single-use and used only with the MediBeacon TGFR system.
Right to Petition or Comment by March 6, 2026
Anyone who believes the dates published are incorrect may submit electronic or written comments and request a redetermination, and any interested person may petition FDA under 21 CFR 60.24 and 60.30 to challenge whether the applicant acted with due diligence; comments and petitions will be accepted through 11:59 p.m. Eastern Time on March 6, 2026. Petitions must be timely, follow specified filing rules, contain sufficient facts, and certify service on the patent applicant.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-24267 — Determination of Regulatory Review Period for Purposes of Patent Extension; IZERVAY
The FDA has officially set the review period for IZERVAY, a human drug, so its patent can be extended. This affects the drug’s makers, who now have clear deadlines to challenge or confirm these dates by early 2026. If all goes well, the patent extension could give them more time to protect their invention and potentially earn more money.
Next: 2025-24269 — Determination of Regulatory Review Period for Purposes of Patent Extension; BRENZAVVY
The FDA has officially set the review period for the drug BRENZAVVY, which helps the company apply for extra patent time. This affects the drug maker and anyone watching patent rules, giving a chance to challenge dates or the company’s effort by early 2026. It’s all about making sure the patent clock is fair and accurate, potentially impacting how long the drug stays exclusive on the market.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in